베타
임상 레이더 AI
임상시험 NCT07413692은(는) 우울 증상, 요실금에 대해 모집중 상태입니다. 모든 세부 정보를 보려면 임상시험 레이더 카드 뷰와 AI 발견 도구를 확인하거나 여기에서 무엇이든 물어보세요.
하나의 임상시험이 필터 기준과 일치합니다.
카드 뷰

BTL-699-2 and HPM-6000UF Devices for the Improvement of Depressive Symptoms and Urinary Incontinence in Postpartum and Early Post-Childbirth Women 60 국제 산후

모집중
임상시험 세부 정보는 주로 영어로 제공됩니다. 하지만 임상 레이더 AI가 도와드릴 수 있습니다! '임상시험 설명'를 클릭하여 선택한 언어로 임상시험 정보를 확인하고, 이에 대해 AI와 논의해 보세요.
임상시험 NCT07413692은(는) 우울 증상, 요실금에 대해 알아보는 중재연구입니다. 현재 상태는 모집중이며, 연구는 2025년 11월 25일에 시작되어 60명의 참여자를 모집하고 있습니다. BTL Industries Ltd.이(가) 진행하며, 2026년 12월 11일까지 완료될 예정입니다. ClinicalTrials.gov의 가장 최근 정보는 2026년 2월 17일에 갱신되었습니다.
간단한 개요
The goal of this clinical trial is to evaluate if the combined treatment with EXOMIND (BTL-699-2) and EMSELLA (HPM-6000UF) devices is able to improve depressive symptoms and urinary incontinence in women who delivered a healthy, singleton infant 2-60 months before enrollment in the study and are aged 22 years and older, but under the age of 60 years. The main question it aims to answer is: Does the combined treatment...더 보기
상세한 설명
This study uses a prospective, multi-center, two-arm, single-blinded, interventional study.

The subjects will be enrolled and randomly assigned to two experimental study arms: the active group (Group A) and the sham group (Group B), in a ratio of 3:1. All enrolled participants will be treated (either active or sham) with both the BTL-699-2 and HPM-6000UF devices. Group A will receive active treatment (BTL-699-2 inte...

더 보기
공식 제목

Safety and Efficacy of the Combined BTL-699-2 and HPM-6000UF Devices for the Improvement of Depressive Symptoms and Urinary Incontinence Among Postpartum Women and Women up to Five Years After Childbirth

질환명
우울 증상요실금
기타 연구 식별자
  • BTL-699_CTUS500
NCT 번호
실제 연구 시작일
2025-11-25
최신 업데이트 게시
2026-02-17
예상 연구 완료일
2026-12-11
계획된 등록 인원
60
연구종류
중재연구
단계/상
해당 없음
상태
모집중
키워드
Depressive Symptoms
Depression
Urinary Incontinence
Incontinence
Postpartum
EMSELLA
ExoTMS
EXOMIND
주요 목적
치료
설계 할당
무작위배정
중재 모델
평행설계
맹검 (마스킹)
단일맹검
시험군 / 개입
참가자 그룹/시험군개입/치료
실험적Active treatment with BTL-699-2 and HPM-6000UF
Participants will receive active treatment (BTL-699-2 intensity: up to 70% of MT, HPM-6000UF intensity: up to 100%)
EXOMIND (BTL-699-2) ActiveTreatment
Participants will receive six transcranial magnetic stimulation treatments with the BTL-699-2 device over the left dorsolateral prefrontal cortex. The intensity will be adjusted according to the subject's feedback, up to 70% of the individual's motor threshold. The treatments will be spaced 3 - 7 days apart.
EMSELLA (HPM-6000UF) ActiveTreatment
Participants will receive six treatments with the HPM-6000UF device delivered to the pelvic floor musculature. The intensity will be adjusted according to the subject's feedback, up to 100%. The treatments will be spaced 3 - 7 days apart.
거짓 대조군Sham treatment with BTL-699-2 and HPM-6000UF
Participants will receive sham treatment (BTL-699-2 intensity: 1% of MT, HPM-6000UF intensity: 1%)
EXOMIND (BTL-699-2) Sham Treatment
Participants will receive six transcranial magnetic stimulation treatments with the BTL-699-2 device over the left dorsolateral prefrontal cortex. The intensity will be set to 1% of the individual's motor threshold. The treatments will be spaced 3 - 7 days apart.
EMSELLA (HPM-6000UF) Sham Treatment
Participants will receive six treatments with the HPM-6000UF device delivered to the pelvic floor musculature. The intensity will be set to 1%. The treatments will be spaced 3 - 7 days apart.
주요결과변수
결과변수측정값 설명시간 범위
Assessment of Change in Self-Reported Symptoms of Depression in Postpartum Women and in Women up to Five Years after Childbirth
The change in the score obtained from the self-reported Patient Health Questionnaire-9 (PHQ-9). The baseline score will be compared to the 1-month follow-up score. The total score from this 9-item questionnaire ranges from 0 to 27, with higher scores indicating greater depression severity. Improvement is considered a decrease in the obtained score.
15 months
이차결과변수
결과변수측정값 설명시간 범위
Assessment of Change in Clinician-Reported Symptoms of Depression in Postpartum Women and in Women up to Five Years after Childbirth
The change in the score obtained from the clinician-reported 6-item Hamilton Depression Rating Scale (HAMD-6). The baseline score will be compared to the 1-month follow-up score. The total score ranges from 0 to 22, with higher scores indicating greater depression severity. Improvement is considered a decrease in the obtained score.
15 months
Assessment of Change in Self-Reported Maternity-Related Symptoms of Depression in Postpartum Women and in Women up to Five Years after Childbirth
The change in the score obtained from the self-reported Edinburgh Postnatal Depression Scale (EPDS). The total score from this 10-item questionnaire ranges from 0 to 30, with higher scores indicating greater depression severity. Improvement is considered a decrease in the obtained score.
15 months
Assessment of Change in Urinary Incontinence in Postpartum Women and in Women up to Five Years after Childbirth
The change in the score obtained from the self-reported International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form (ICIQ-UI SF). The total score ranges from 0 to 21, with higher total score indicating greater symptom burden and impact.
15 months
Assessment of Change in Sexual Function in Postpartum Women and in Women up to Five Years after Childbirth
The change in the score obtained from the self-reported 6-item Female Sexual Function Index (FSFI-6). The total score ranges from 2 to 30, with lower scores indicating poorer sexual function.
15 months
Assessment of Change in Mental Well-Being in Postpartum Women and in Women up to Five Years after Childbirth
The change in the score obtained from the self-reported Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS). The minimum scale score is 14 and the maximum is 70. Improvement is considered an increase in the obtained score. The WEMWBS will be filled out at baseline, at the last treatment visit, and at both follow-up visits.
15 months
Assessment of Satisfaction
Subject Satisfaction with treatment outcomes will be assessed using 5-point Likert Scale Subjects Satisfaction Questionnaire. The questionnaire will be administered after the last treatment, at the 1-month and 3-month follow-up visits. Responses to questions about satisfaction with the treatment outcomes will range from "strongly disagree" (1 point) to "strongly agree" (5 points). A higher score for each statement indicate better outcomes.
15 months
Assessment of Therapy Comfort
Therapy Comfort questionnaire will be used for evaluating the comfort during the treatment sessions. The Therapy Comfort questionnaire will be administered after the last treatment. Therapy Comfort questionnaire consists of the question "I found the treatment comfortable", to which responses are based on a 5-point Likert scale (1 = "strongly disagree", and 5 = "strongly agree"). A higher score for the statement "I found the treatment comfortable" indicate higher therapy comfort.
15 months
Incidence of Treatment-related Adverse Events
Monitoring of adverse reactions and side effects will be performed for the evaluation of safety of the combined treatment with the BTL-699-2 and HPM-6000UF devices for the improvement of depressive symptoms and urinary incontinence and to identify side effects and adverse events associated with the study treatment.
15 months
Assessment of Pain During Therapy
The Therapy Comfort Questionnaire will be used to evaluate pain experienced during the treatment session. It will be administered after the stimulation of each location. The questionnaire includes a 10-point Numeric Analog Scale for pain (0 = no pain, 10 = worst possible pain). Lower scores on the Numeric Analog Scale indicate lower levels of pain.
15 months
참여 도우미
적격성 기준

연령대
성인
최소 연령
22 Years
참여 가능한 성별
여성
  • Delivery of a healthy, singleton infant 2-60 months before enrollment in the study
  • Current involvement in caregiving or regular contact with the child in question
  • Patient Health Questionnaire-9 (PHQ-9) pre-treatment score of ≥ 5
  • Age ≥ 22, but ≤ 60 years
  • Ability to determine the motor threshold of the participant. The participant's motor threshold could be established as the minimum stimulus required to induce contraction of the finger
  • Subjects willing and able to abstain from partaking in any treatments other than the pre-procedure therapy regime for the treatment of depressive symptoms and/or urinary incontinence, including non-invasive brain stimulation treatments other than the study procedure during study participation
  • Willingness to comply with study instructions and to return to the clinic for the required visits
  • Subjects are required to use birth control measures throughout the study if there is a reasonable possibility they could become pregnant during the study
  • If applicable, subjects will be maintained on a pre-study psychotherapeutic regimen and/or prescribed neuropsychiatric medications at a stable therapeutic dosage for at least 1 month prior to study entry

  • Metallic objects in or near the head
  • rTMS devices are contraindicated for use in patients who have conductive, ferromagnetic or other magnetic-sensitive metals implanted in their head or within 12 in (30 cm) of the treatment coil*
  • Implanted stimulator devices, implanted defibrillators, implanted neurostimulators
  • Cardiac pacemakers
  • Electronic implants
  • Metal implants
  • rTMS devices are contraindicated for use in patients who have active or inactive implants (including device leads), including deep brain stimulators, cochlear implants, ocular implants and vagus nerve stimulators. Contraindicated use could result in serious injury or death.
  • Drug pumps
  • Application in the heart area
  • Application of HPM-6000UF in the head area
  • Persons with a tendency to seizure (e.g., persons suffering from hypotonia and epilepsy)
  • Anticoagulation therapy
  • Severe or life-threatening condition
  • Pulmonary insufficiency
  • Heart disorders
  • Renal insufficiency
  • Decompensated** hemorrhagic conditions
  • Decompensated** blood coagulation disorders
  • Decompensated** cardiovascular diseases
  • Malignant tumor or benign tumor
  • Fever
  • Pregnancy

Study specific:

  • Active suicidal intent

  • History of suicide attempts in the last 3 years before enrollment in the study

  • Substance-induced depression or depression secondary to a general medical condition

  • Diagnosis of seasonal affective disorder, psychotic disorder including schizoaffective disorder or current psychotic symptoms, major depression with psychotic features, bipolar disorder, borderline personality disorder

  • Current episodes of substance abuse

  • Substance dependence 3 months before enrollment in the study

  • History or concurrent use of electroconvulsive therapy or vagus nerve stimulation

  • Neurological disorders, including a history of seizures, cerebrovascular disease, primary or secondary tumors in CNS, cerebral aneurysm, dementia, or movement disorders

  • History of increased intracranial pressure or head trauma

  • Any other disease or condition at the investigator's discretion that may pose risk to the patient or compromise the study

    • Examples include cochlear implants, implanted electrodes/stimulators, aneurysm clips or coils, stents, bullet fragments, jewelry and hair barrettes. Failure to follow this restriction could result in serious injury or death. Certain exceptions apply to mouth implants such as standard amalgam dental fillings, single post dental implants, dental bridge work, and braces. If these items are present, the therapy can still be administered. **By means of decompensation, it means a patient with a proven medical history of the decompensated health condition and long-term medication. Patients who use certain medications only for preventive purposes, without any proven previous health condition failure are not considered contraindicated.
BTL Industries Ltd. logoBTL Industries Ltd.
연락처 정보가 없습니다.
3 1개국에 임상시험 장소

Ohio

Charak Center for Health & Wellness, Garfield Heights, Ohio, 44125, United States
Rakesh Ranjan, MD, 연락처, (216) 587-6727, [email protected]
모집중

Oklahoma

Optimal Health Associates, Oklahoma City, Oklahoma, 73114, United States
Noel Williams, MD, 연락처, (405) 715-4496, [email protected]
모집중

Texas

Tricia Shimer, M.D., P.A., Dallas, Texas, 75231, United States
Tricia Shimer, MD, 연락처, (469) 214-4390, [email protected]
모집중